Anupam Rasayan buys 50.07% of Bliss GVS in 2026

Disclosure that flagged the control change

Stock exchange disclosures under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST) indicated a key ownership shift in Bliss GVS Pharma Ltd. The filing said the exchange received the disclosure for Anupam Rasayan India Ltd in relation to Bliss GVS Pharma.

The disclosure timeline referenced updates around late September and early October 2026, including an item dated 01 October 2026 (09:01 am, Source: BSE). Another exchange update highlighted that control was transferred on 28 September 2026, after Anupam Rasayan and persons acting in concert (PAC) crossed the majority threshold.

For investors, these filings matter because SAST disclosures are the formal trail for material stake changes, the identity of the acquirer, and whether a transaction results in a change of control.

What the exchange filing said about the acquisition

According to the disclosure, Anupam Rasayan India and its PAC acquired 5,09,84,595 shares of Bliss GVS Pharma on 28 September 2026. This block represented a 47.95% stake.

The filing further stated that this acquisition brought their total combined holding to 50.07%. Crossing 50% was presented as triggering a change in control and establishing Anupam Rasayan India and PAC as the new promoters.

The same set of announcements also referenced that “Anupam Rasayan and PAC acquired 50.07% of Bliss GVS; control transferred on 28 September 2026,” reinforcing the control-transfer date mentioned in the disclosure.

Earlier purchase: 2.12% stake for ₹162.74 crore

Separate reporting in the provided text said specialty chemicals manufacturer Anupam Rasayan India acquired 22.5 lakh shares of Bliss GVS Pharma, representing a 2.12% stake, for ₹162.74 crore.

This data point is important in context because it shows buying activity in Bliss GVS before the later disclosure that took the combined holding beyond 50%. The text does not specify whether the 2.12% purchase formed part of the same sequence of acquisitions that culminated in the control transfer, so it should be read as a reported transaction alongside the later SAST disclosure.

The May 2026 share purchase agreement and deal size

The background section in the provided material referenced a disclosure from May 2026, stating that certain promoter and non-promoter shareholders of Bliss GVS had entered into a Share Purchase Agreement (SPA) with Anupam Rasayan India Ltd.

The proposed acquisition under the SPA was described as approximately 43.28% of the paid-up equity share capital for ₹1,369 crore, subject to regulatory approvals and other closing conditions. This is a key anchor figure because it frames the transaction as a structured promoter stake transfer rather than only market purchases.

The same May 2026 disclosure also stated that the transaction triggered a mandatory open offer for up to an additional 26% stake from public shareholders.

What “mandatory open offer” means here

The text explicitly notes that the SPA-triggered transaction led to a mandatory open offer for up to 26% from public shareholders. Under SAST, an open offer is typically required when an acquirer crosses specified thresholds or acquires control.

In this case, the only details available in the provided content are the maximum open-offer size (up to 26%) and that the open offer was triggered. The offer price, timelines, and other open-offer terms are not provided in the supplied text.

About Bliss GVS Pharma: business and history

Bliss GVS Pharma Limited was incorporated in 1984, according to the text provided. The company is described as being engaged in manufacturing, marketing, trading, and export of pharmaceutical formulations.

The product forms listed include suppositories, pessaries, capsules, tablets, and syrups. This context helps explain why the change in control could be tracked closely by investors, especially given Bliss GVS is an operating pharmaceutical formulations business.

Shareholding context mentioned in the material

The provided text also included a snapshot-style statement that “Promoters hold 35.4% of Bliss GVS Pharma Ltd,” along with “Foreign institutions hold 10.4% and domestic institutions 5.0%,” noting that none of the promoter holding is pledged.

It further said these figures are from the latest quarterly shareholding filing and that two mutual fund schemes disclose a holding in Bliss GVS Pharma Ltd. The material also noted “Bliss GVS Pharma promoters reclassified to public after Anupam Rasayan takes control,” indicating a shift in promoter classification following the change in control.

Market data points included in the text

The excerpt contained two market references: a market capitalisation figure and a current price figure. It listed Market Cap at ₹7,337 crore and Current Price at ₹690.

These values provide context to the scale of the transaction relative to the company’s market size, but the text does not provide the date for the market cap and price snapshot.

Key facts table

Timeline of the events referenced

Market impact: what investors can infer from the filings

The immediate market impact stated in the provided text is the change in control and the identification of new promoters at Bliss GVS Pharma. The material also points to a mandatory open offer for up to 26%, which is a concrete procedural consequence for public shareholders.

Beyond that, the text does not provide post-announcement price movement, volumes, or updated financial performance figures. So any market reaction should be interpreted only through the disclosed numbers: a move to 50.07% holding and the related open-offer requirement.

Analysis: why the 50% threshold matters

The control transfer at 50.07% is significant because it marks a shift from a minority strategic holding to promoter-level control. The disclosure explicitly frames the outcome as a “change in control,” which can affect governance, board composition, and promoter classification in future filings.

The data also shows that the transaction had multiple layers: an SPA for a large promoter block (~43.28%), reported purchases such as a 2.12% stake buy for ₹162.74 crore, and then the disclosure of the acquisition that lifted combined holding above 50%. This sequencing, as presented, is consistent with how control transactions are often structured under India’s takeover rules, with disclosures and open-offer obligations.

Conclusion

Exchange disclosures under SEBI SAST Regulation 29(1) show Anupam Rasayan India and its PAC becoming the new promoters of Bliss GVS Pharma after taking their combined holding to 50.07% and transferring control on 28 September 2026. The background provided also cites a May 2026 SPA for ~43.28% valued at ₹1,369 crore and a mandatory open offer for up to 26%.

The next concrete milestones for investors, based on the material provided, are further exchange filings tied to SAST disclosures and any detailed open-offer documentation that may be released through official channels.